Conference Interview #3 of 12
Liz Meszaros, MDLinx
Iselin, New Jersey, United States | November 13-14, 2017
The partnership was launched in July 2016 to address and fill the gaps in antibiotic research, development, and innovation in improving the diagnosis and treatment of drug-resistant infections. John H. Rex, MD, FACP, chief medical officer, F2G Ltd., Manchester, UK, explains the inception of CARB-X, its goals, and achievements.